Oscar Health Confirms Strong Q1 Profitability and Membership Growth; CEO Makes Significant $11.9M Stock Purchase
summarizeSummary
Oscar Health reported a strong return to profitability in Q1 2026 with significant revenue and membership growth, alongside a substantial $11.9 million stock purchase by its CEO and a new $475 million credit facility.
check_boxKey Events
-
Strong Q1 Profitability
Oscar Health reported net income attributable to Oscar Health, Inc. of $679.0 million for Q1 2026, a significant improvement compared to a net income of $275.3 million in Q1 2025 and a net loss of $443.15 million for fiscal year 2025.
-
Robust Revenue Growth
Total revenue increased by 53% to $4.65 billion in Q1 2026, up from $3.05 billion in Q1 2025, driven by higher membership and premium rate increases.
-
Significant Membership Increase
Effectuated members grew by 56% year-over-year to approximately 3.2 million as of March 31, 2026, primarily due to above-market growth during the 2026 Open Enrollment Period.
-
Improved Efficiency Ratios
The Medical Loss Ratio (MLR) decreased to 70.5% in Q1 2026 from 75.4% in Q1 2025, and the SG&A expense ratio decreased to 15.2% from 15.8%, reflecting disciplined pricing and cost management.
auto_awesomeAnalysis
This 10-Q filing confirms Oscar Health's significant financial turnaround in Q1 2026, building on the preliminary results announced in the recent 8-K. The company reported substantial net income and robust revenue growth, a stark contrast to the net loss reported for fiscal year 2025. This positive performance is further bolstered by a notable increase in membership and improved efficiency metrics. Adding to the positive sentiment, CEO Mark T. Bertolini made a substantial open-market purchase of $11.9 million in Class A common stock, signaling strong insider confidence. The establishment of a new $475 million revolving credit facility also enhances the company's liquidity and financial flexibility. While the filing notes potential future impacts from regulatory changes and proposed tariffs, the immediate financial results and strategic moves indicate a strong operational trajectory.
At the time of this filing, OSCR was trading at $20.73 on NYSE in the Finance sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $10.69 to $23.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.